3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Surveys and Questionnaires
2
Standard of Care
2
Radiosurgery
2
Practice Guidelines as Topic
2
Oxaliplatin
2
Nivolumab
2
Leucovorin
2
Fluorouracil
2
tislelizumab
1
irinotecan sucrosofate
1
folfirinox
1
fludarabine
1
encorafenib
1
durvalumab
1
canakinumab
1
avatrombopag
1
aldesleukin
1
Transurethral Resection of Prostate
1
Sodium Chloride
1
Restraint, Physical
1
Remote Patient Monitoring
1
Radiotherapy
1
Psilocybin
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Panitumumab
1
Observation
1
Massage
1
Magnetic Resonance Spectroscopy
1
Levoleucovorin
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Gastrointestinal Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled